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Abstract 
 
Objective: Health technology financing is often based on randomized controlled trials (RCTs), 
which are often the same ones used for licensing. Since they are designed to show the best 
possible results with typically Phase III studies conducted under ideal and highly controlled 
conditions to seek high internal validity and maximize the chance of demonstrating clinical benefit, 
they often do not reflect likely effectiveness in routine clinical care. Consequently, it is not 
surprising that technologies do not always perform in real life in the same way as controlled 
conditions. Since financing (and price paid) decisions can be made with overestimated results, 
health authorities need to ask whether health systems achieve the results they expect when they 
choose to pay for a technology. The optimal way to answer this question is to assess the 
performance of financed technologies in real world settings. Health technology performance 
assessment (HTpA) refers to the systematic evaluation of the properties, effects, and/or impact of 
a health intervention or health technology in the real world to provide information for 
investment/ disinvestment decisions and clinical guideline updates. The objective is to describe 
the development and principal aspects of the Guideline for HTpA commissioned by the Brazilian 
Ministry of Health. Method: Extensive literature review, refinement with experts across countries 
and public consultation. Results: A comprehensive guideline was developed, which has been 
adopted by the Brazilian government. Conclusion: We believe the guideline, with its particular 
focus on disinvestment, along with the creation of a specific program for HTpA, will allow the 
institutionalization and continuous improvement of the scientific methods to use real world 
evidence to optimize available resources not only in Brazil but across countries.  
 
Keywords: Technology Assessment, Biomedical; Observational studies; Health policy; Health 
Information Systems  
 
Policy implications: Real-world evidence is emerging as an important tool to aid decision-making 
regarding health technology financing. Over the last decade, countries have developed  health 
and/ or administrative registries capable of providing quality data for assessing health results in 
real life. At the same time, budgetary constraints and the pressure to finance emerging high-priced 
technologies are making it inevitable for health authorities to start assessing whether patients and 
society are getting the results from financed technologies agreed upon during investment 
decisions. This paper presents the concept of Health Technology performance Assessment and the 
development of a guideline, commissioned by the Brazilian Ministry of Health, to implement such 
activity. We believe it is the first guideline to formally incorporate the use of real-world evidence 
for updating clinical guidelines, price renegotiation and disinvestment decisions.  
 1. INTRODUCTION 
In many developed and developing countries, decision-making regarding health technology 
funding is based on results from Health Technology Assessments (HTA) (1, 2). These assessments 
often include the same studies conducted for licensing  ? the randomized clinical trials (RCTs), 
ǁŚŝĐŚĂƌĞĐŽŶƐŝĚĞƌĞĚƚŽƉƌŽǀŝĚĞ ?ŐŽůĚƐƚĂŶĚĂƌĚ ?ĞǀŝĚĞŶĐĞ ?3). However RCTs, especially those 
conducted by the manufacturer, have important limitations. Since they are designed to show the 
best possible result for the new technology, i.e. typically Phase III studies are conducted under 
ideal and highly controlled conditions to seek high internal validity and maximize the chance of 
demonstrating clinical benefit (4), they frequently select patients more likely to present the best 
response, and do sometimes use placebo as a control even when standard treatment already 
exists (5). As a result, it is expected that technologies do not always perform in real-life in the 
same way as they performed in controlled conditions. As consequence, RCTs can fail to offer 
evidence of the effectiveness of technologies in routine clinical care especially as patients may well 
be older and more co-morbid than those contained in RCTs (6).  
Beyond concerns with RCTs, inherent limitations in a number of studies used for HTA decisions 
include the use of surrogate measures and secondary outcomes, using grouped outcome 
measures, using a single pivotal trial or over-powering trials, all of which may enhance the efficacy 
and/ or understate the adverse effects of technologies. Concerns with surrogate markers have 
been highlighted in a number of situations (7-10). It has also been shown that in the USA single 
pivotal trials gave support to almost a third of new drug approvals from 2005-2012. More than 
two thirds of new drugs were also approved on the basis of studies lasting six months or less 
(11,12). Adding to this, despite ethical and statutory mandates, lack of transparency and 
publication bias are still major concerns. For instance, it has been shown that less than 50% of 
RCTs are published in a five-year window since registering them 0nto ClinicalTrials.gov (13).  
Furthermore, scientific methods used to assess whether or not it is worth paying for new higher 
priced technologies are typically based on evidence provided by the manufacturer and tend to 
favor the perception that it is, indeed, worth paying a premium price. The consequence is the 
potential of ever increasing healthcare expenditure as each newly reimbursed technology is used 
to establish new cost-effectiveness threshold levels (14). This is a concern as a number of 
countries are struggling to fund new higher priced medicines, which is not in the best interest of 
any key stakeholder group (4). In addition, most countries that use economic analyses for 
reimbursement decisions are still reluctant to set economic threshold levels (1). Authors have 
argued that by defining a threshold, health authorities are setting and disseminating a price ceiling 
to which manufacturers will seek to reach instead of negotiating lower prices (15). This has 
consequence of pushing up prices and increasing the burden on public health budgets, as seen for 
instance with new cancer medicines and those for orphan diseases (16,17). Even in cases where 
health authorities choose to set a threshold value, there are debates in literature that lower 
thresholds should be established for new medicines in prevalent conditions (15) as the current 
threshold levels are seen as too high (18), especially with little empiric basis for establishing these 
values.  
Adding to this, after new technologies are incorporated into reimbursement lists, there is often 
limited further evaluation of their real value unless they are part of managed entry agreements 
(19). This is a concern both in terms of opportunity costs as well as patient care. For instance, 
meta-analyses and independent cohort studies have continued to show no difference in 
effectiveness between isophane insulin, rDNA insulins and long acting insulins despite 
considerable differences in prices (20). In other case, studies have shown surprisingly differing 
results in real life in the case of medicines for transplantation (21). On the other hand despite early 
concerns, long-term cohort studies have demonstrated the effectiveness and safety of TNF alpha 
inhibitors in patients with immune diseases although the effectiveness of treatments in real-life 
may be different from those seen in randomized clinical trials (22). These situations raise the 
question of whether health systems actually obtain the results they are expecting when they 
choose to pay for new technologies. 
In light of this, we believe new approaches are needed to continually re-assess technologies and 
evaluate their performance in the real world given continuing pressure on resources. In this article 
we describe the development of the Guideline for Health Technology performance Assessment 
produced by the SUS Collaborating Centre for Technology Assessment and Excellence in Health 
(CCATES) in collaboration with many international experts and the support of the Pan-American 
Health Organization (PAHO) and the Department of Management and Incorporation of 
Technologies from Brazilian Ministry of Health. The objective of the Guideline was to stablish the 
monitoring of funded technologies using real world evidence to assess their performance and 
update clinical guidelines. The main focus will be on disinvestment as this is a growing area of 
interest given pressure on resources. We hope this will be of interest not only in Brazil but wider.  
2. HEALTH TECHNOLOGY PERFORMANCE ASSESSMENT  
Health technology performance assessment (HTpA) refers to the systematic evaluation of 
properties, effects, and/or impacts of a health intervention or health technology in the real world. 
It provides information to health systems to support the update of clinical guidelines and/ or 
continued reimbursement by contrasting health and safety results in the whole population with 
initial RCT information. The HTpA matches real life results with technology values. In the process 
of evidence based decisions, HTpA is undertaken after a positive reimbursement/public provision 
decision, leading to clinical guideline updates (Figure 1). In Brazil, the inclusion of new 
technologies in updated clinical guidelines is essential for their reimbursement within the public 
health system (SUS); otherwise they are not reimbursed (20,23).  
 
 
Figure 1. Process of evidence-based decisions. Health Technology performance Assessment is the 
evaluation of the results of financed technologies in real-world settings 
 
 
HTpA may indicate the need to disinvest in one or more of the four modalities as shown below 
(adapted from Daniels et al. (24):  
x Full delisting - Delisting of the technology. It is the most difficult modality to implement 
and has great potential for unmanaged substitution;  
x Restriction - The provision of the technology will be restricted to groups or subgroups of 
users, with strictly criteria for its use. It may be seen as discriminatory. It can be reversed 
or enlarged as required;  
x Retraction - The technology will be supplied in a smaller amount to each individual, e.g. 1 
mammogram/ year instead of 2. Potentially more acceptable than full delisting;  
x Substitution - The currently offered technology will be replaced by a cost-effective 
alternative, ensuring equivalent treatment/service.  
3. Price renegotiations may be applied with restrictions to defined patient populations to 
help target resources to the patient populations of highest value. This may be preferable 
to not reimbursing patented medicines in a class once generics become available in that 
class. DEVELOPMENT OF THE GUIDELINE  
A review was conducted to identify necessary aspects to be addressed in the guideline. Scientific 
literature and HTA Agencies/Government were scanned for eligible reports. Key-principles for 
HTpA were adapted from HTA principles (50), which helped orientate the development of the first 
draft of the guideline. Similar to HTA, the performance assessment must be current and timely, its 
scope should be explicit and relevant, and the process must be transparent and actively involve 
interested stakeholders. When only a few technologies are evaluated, there must be a clear 
process of selection of these technologies in order to avoid distortions in investment decisions and 
to ensure transparency. HTpA should be conducted with appropriate and rigorous methods for 
assessing costs and benefits, in order to generate confidence among key stakeholders including 
the general public in its conclusions. Even though HTpA reports must be designed and/ or destined 
to health authority managers with clear and objective recommendations, it is important to 
develop strategies to disclose the study and its conclusions to the different social actors. 
3. RESULTS 
3.1 Development of the first version of the guideline using Ă ?ƐŶŽǁďĂůů ?ƚĞĐŚŶŝƋƵĞ ? 
Public health researchers, health managers and policymakers were invited to contribute via email 
and in meetings held by CCATES to help develop the guideline. After receiving contributions to the 
draft, the first version of the guideline was developed. One of the proposals to the draft was the 
implementation of a program to institutionalize the continuous assessment of incorporated health 
technologies. The implementation of such a program would serve as a landmark for the possibility 
of disinvestment for all existing technologies and for all technologies candidates for potential 
incorporation.  
The guideline was divided in eight sections: (i) Introduction; (ii) Steps of disinvestment process (iv - 
vii); (iii) Permanent program for assessing the performance of technologies; (iv) Identification of 
potential technologies for disinvestment; (v) Prioritization; (vi) Health Technology Reassessment; 
(vii) Implementation of disinvestment decision; and (viii) Final Remarks. This version was entitled 
 ?ŝƐŝŶǀĞƐƚŵĞŶƚ'ƵŝĚĞůŝŶĞWƌŽƉŽƐĂů ? ? 
The proposed activities for the permanent program for assessing the performance of technologies 
were:  
(i) the continuous monitoring of the effectiveness of financed technologies;  
(ii) the establishment of a legal framework and of organizational mechanisms to enable and 
facilitate technology disinvestment where pertinent;  
(iii) the active search for candidate technologies for disinvestment and;  
(iv) monitoring the impact of the disinvestment.  
We proposed that the health technology indication for performance assessment could arise from 
within health systems or from society. To be eligible for HTpA, a reimbursed/provided technology 
must comply with at least one of the requirements as specified in  Table 1  
  
Table 1.  Criteria for identification of financed health technologies for Health Technology 
performance Assessment 
IDENTIFICATION OF HEALTH TECHNOLOGIES 
Criteria Possible indicatives 
Safety 
There is unacceptable potential safety risk for users, society or the 
environment related to the use of technology; 
There is evidence demonstrating that the technology generates 
unacceptable risk-benefit concerns; 
There is evidence showing that new technologies get the same results, 
but record significantly higher levels of safety. 
Effectiveness 
Absence or low evidence of efficacy and effectiveness of the technology;  
There is evidence showing inefficacy and ineffectiveness of the 
technology in one or more indications;  
There is evidence showing that new/other technologies with the same 
results have better cost-effectiveness ratio;  
There is evidence showing that new technologies, with the same price, 
record higher levels of efficacy/effectiveness. 
Cost 
There is evidence demonstrating that the monetary value of the 
technology is not translated in the proposed benefit;  
There is evidence showing that there are other technologies that provide 
the same results with lower prices/ costs;  
There is no reduction of the technology price over time, showing to be 
non-competitive with other cheaper technologies that guarantee the 
same results. 
Cost- effectiveness 
There is evidence proving that a competitive technology presents a 
better cost-effectiveness ratio than that available.  
Disuse 
There is evidence showing that the technology is no longer being used 
by the users of the health system. 
Inappropriate use 
There is evidence showing that the technology is being improperly used. 
For example, in excess, or when it is used by groups for which the 
technology is not intended to. 
Logistics 
There is evidence showing that a competitive technology, with the same 
results, needs a simplified logistics plan, with proven lower costs, 
showing to be more suitable to the conditions of use. 
Availability 
The unavailability of the technology in the market, due to, for example, 
deviation of the quality during production, the non-renewal of the 
registration of marketing or the interruption of production.  
The unavailability of essential material or accessory for the proper 
functioning of the technology.* 
Acceptability 
There is evidence showing that the technology produces important 
discomfort/pain, undesirable side effect that causes the interruption of 
treatment;  
There is evidence showing that the technology produces negative 
repercussions because it is considered "invasive";  
There is evidence showing that the technology leads to poor quality of 
life of the users;  
There is evidence showing that the technology records relevant levels of 
nonadherence. 
Adequacy 
There is evidence showing that the technology is considered by health 
professionals as not relevant for clinical practice. 
Contraindications 
There is evidence showing that after the incorporation, the technology 
has relevant contraindication that endangers or limits the use by 
patients in clinical practice. 
 
&ŽƌƉƌŝŽƌŝƚŝǌĂƚŝŽŶ ?ǁĞƵƐĞĚ ?DƵůƚŝĐƌŝƚĞƌŝĂĞĐŝƐŝŽŶŶĂůǇƐŝƐ ?ŝŶĐŽƌƉŽƌĂƚŝŶŐsĂůƵĞDĞĂƐƵƌĞŵĞŶƚ
Models, using criteria adapted from those proposed by Elshaug et al. (2009) (26) and those used 
by the Canadian Agency for Drugs and Technologies in Health (CADTH) for prioritizing technologies 
for evaluation in the context of incorporation (27).  
The HTpA section addresses the performance assessment modalities (full withdrawal/full delisting; 
restriction; retraction and substitution); price renegotiation; the HTpA process itself; and the 
elaboration of recommendations to health managers. It also addresses the need to indicate in the 
HTpA report a period of time sufficient to implement the decision  ? the transition period.  
The Implementation of any disinvestment decision resulting from the performance assessment 
section should address the organizational implications to be taken into account and overcome by 
health manages. This includes the necessity to redistribute, hire and train personnel and the 
necessity to implement reverse logistics measures to collect any remaining disinvested products, 
i.e. medicines, medical devices, etc. In addition, decisions may address the necessity to update 
clinical protocols and to produce different versions of the same protocol to reach different 
stakeholder groups, e.g. health professionals, health managers, politicians and patients.  
The strategies for the dissemination of any decision should focus on the main social actors 
involved in the provision of the technology. All media should aim at transparency explaining the 
decision, and there should be clear explanations of the causes and consequences of any 
subsequent disinvestment decision to ensure full understanding of those who provide and use the 
technology, as well as to prevent the occurrence of unmanaged substitution and any judicial 
demands. Judicial demands are particularly prevalent in Brazil as seen with insulin glargine (20). 
Suggested strategies to address this include academic detailing, production and dissemination of 
videos and bulletins, and the creation of a direct communication channel to address potential 
doubters.  
3.2 Development of the second version of the guideline after the panel of experts to discuss key 
points and clinical cases to improve the document.  
In November 2015, an International Panel on Disinvestment was held at UFMG. This includes 
representatives from the Brazilian Ministry of Health; PAHO; the University of Strathclyde, UK; 
Karolinska Institute, Stockholm, Sweden and Stockholm County Council, Sweden; OSTEBA (Basque 
HTA), Fondo Nacional de Recursos (Uruguay); National Prescribing Service (Australia), and 
Universidad Nacional del Litoral (Argentina) to review the first version of the guideline.  
As basis for debate, in small group sessions, participants were invited to assess two performance 
assessment case studies, one focused in specialized care, i.e. evidence of the comparative 
effectiveness of beta interferon 1A 6,000,000 IU (30 µg) for multiple sclerosis, and the other in 
primary care regarding insulin analogue glargine. Both cases were accompanied by real-life 
evidence of effectiveness.  
The most important decision arrived from the panel was to change the focus of the guideline from 
disinvestment to technology monitoring and clinical guideline update. The first discussion by the 
ƉĂŶĞůŝƐƚƐĐŽŶĐĞƌŶĞĚƚŚĞƚĞƌŵ ?ĚŝƐŝŶǀĞƐƚŵĞŶƚ ? ?ǁŚŝĐŚǁĂƐĐŽŶƐŝĚĞƌĞĚƚŽŚĂǀĞĂŶĞŐĂƚŝǀĞƚŽŶĞ ?ĂŶĚ
ƚŽďĞĨƌĞƋƵĞŶƚůǇĂƐƐŽĐŝĂƚĞĚǁŝƚŚĂ ?ůŽƐƐŽĨƌŝŐŚƚƐ ?ĂŶĚƚƌĞĂƚŵĞŶƚĚĞŶŝĂů ?ĂŶĚŶŽƚĂƵƚŽŵĂƚŝĐĂůůǇ
associated with opportunity costs. In addition, as shown previously in the first version, 
technologies need to be continuously evaluated after financing decisions - this action was 
summarized under the term Health Technology performance Assessment.  
Another important decision was to explicitly indicate to key stakeholder groups that continuous 
funding of a given technology is conditional on the beneficial results in real life, and this is a valid 
statement for technologies yet to be financed. Another relevant aspect that was later included in 
the guideline was the need for horizon-scanning programs to work closely with programs for 
assessing the performance of technologies in routine clinical care in order to identify key potential 
areas for disinvestment and avoid unnecessary evaluations.  
In the updated version, two different overlapping flow diagrams were proposed, one for 
technologies not yet financed, and one for already financed ones (Figure 2). For already financed 
technologies, prioritization criteria were updated to include the rate of launching of new 
technologies  ? technologies from fast evolving areas may be prioritized since there may be a 
greater chance for substitution (Table 2). It is noteworthy that older technologies can sometimes 
have worse evidence as seen in the review of older medicines that had been superseded by newer 
more effective medicines in France (28). However, this may not always be the case as seen with 
tacrolimus versus cyclosporine and insulin glargine versus NPH insulins in Brazil (20,21). Overall 
though, older funded technologies may be prioritized for HTpA to assess their continued funding. 
In addition, after the institutionalization of HTpA, not all technologies incorporated would be a 
priority for assessment. Technologies with high cost per treatment or high unitary cost, recently 
licensed technologies, and technologies/treatments considered groundbreaking may be prioritized 
for HTpA. Examples shaping utilization and funding including real world studies with the anti-TNF 
alphas for rheumatoid arthritis where fears of increased rates of cancer and infection have not 
been realized in practice (22) and the WOSCOPS study in Scotland where 20 year follow-up of 
statin therapy for 5 years is associated with improved survival and a substantial reduction in 
cardiovascular outcomes, supporting the wider adoption of primary prevention approaches (29).  
 
  
Figure 2. Flow diagrams for HTpA implementation. For financed technologies, HTpA may be 
suggested by any member of society  ? patients, health professionals, medical society, industry, 
etc. For technologies yet to be financed, appointment for HTpA may be assessed during or right 
after incorporation 
 
 
Table 2. Criteria for prioritization of financed health technology for HTpA 
PRIORITIZATION 
Criteria Explanation 
Safety issue 
Among the identified technologies, the ones related to health risks 
should be prioritized 
Cost of service 
High cost per procedure, high cost due to the volume, or an aggregate 
measure of both 
Probable impacts 
Related to health: e.g., gross estimate of quality-adjusted life year; 
Related to costs: e.g., gross estimated of savings per patient; release of 
additional resources, etc; Overall assessment of the maintenance of 
equity in care, if the financing of health technology is modified (e.g., 
access for subgroups of patients) 
Cost-effective 
alternative 
Priority should be given to technologies for which there are cheaper 
alternatives with equivalent or better results 
Burden of disease 
Conditions associated with low disability or morbidity or low mortality 
rates (excluding orphan diseases) can influence the prioritization of 
different health conditions with high disability / morbidity or mortality. 
Low burden conditions may reduce the potential for dispute; high 
burden diseases can represent a greater scope for reinvestment / 
reallocation of resources 
Sufficient evidence 
available for 
decision 
Rigorous assessment requires robust evidence. Typically the evidence is 
not 100% conclusive, but they must be suitable to be useful in decision 
making 
Possibility to 
generate evidence 
for decision-making 
Time and budget possibility of conducting a study to support decision 
making when there is little evidence available 
Futility 
An intervention that probably does not result in "significant survival" or 
benefit can be prioritized 
Possible political 
impact 
Interventions in areas where there is political engagement should be 
carefully evaluated, because this can be considered more or less priority 
depending on the political moment 
Rate of launch of 
new technologies 
Technologies used for diseases that are the focus of scientific and 
industrial interest should be prioritized. Often new technologies are 
launched in the market (greater possibility of replacement technology) 
Adapted from: Elshaug et al. (2009) (26) and Husereau et al. (27) 
 
Technologies prioritized to HTpA will be evaluated using real-world evidence and incorporating 
resource utilization data in view of potential concerns. As part of this, it is recommended that a 
permanent program be established for monitoring the clinical effectiveness and the quality of use 
of medicines, procedures and equipment in Brazil in routine clinical care. It is responsibility of the 
ƉƌŽŐƌĂŵ ?ƐƐƚĂĨĨƚŽĐŽŽƌĚŝŶĂƚĞŚŽƌŝǌŽŶƐĐĂŶŶŝŶŐĂĐƚŝǀŝƚŝĞƐ ?ƌĞĐĞŝǀĞĞǆƚĞƌŶĂůrequests and for 
prioritization of activities. The design and conduct of any HTpA studies may be undertaken in 
cooperation with academic units taking into account any conflicts of interest. Society involvement 
in all stages of HTpA is highly recommended, both because HTpA includes the collection of 
outcomes from patients in real life and societal participation enhances the acceptability of 
disinvestment activities.  
3.3 Presentation and debate in the National Commission for Health Technology Incorporation 
(CONITEC/Brazil) and public consultation via online form in CONITEC/Brazil 
After presenting the Guideline to the plenary of CONITEC/Brazil, the proposal was submitted to 
public consultation in March 2016. A total of 89 comments were received through the online form 
in the CONITEC/Brazil website. Most of the contributors were from pharmaceutical companies. 
dŚĞĂƵƚŚŽƌ ?ƐĂŶƐǁĞƌƐĨŽƌƚŚĞŬĞǇƉŽŝŶƚƐƌĂŝƐĞĚďǇĐŽŶƚƌŝďƵƚŽƌƐǁĞƌĞ P 
x Appropriateness of the guideline for technologies for rare diseases  
For rare diseases, the HTpA would be guided by effectiveness and safety results. It is noteworthy 
that in the absence of therapeutic alternative technologies for rare diseases, they probably would 
not be candidates for full delisting. However, these technologies should be evaluated for price 
adjustments where this is a concern as well as the identification of patient sub-groups who may 
truly benefit from the technology. This follows the experiences in the Netherlands with enzyme 
replacement therapy for Fabry and Pompe disease where pressure was exerted on the Ministry of 
,ĞĂůƚŚƚŽĨƵŶĚƚŚĞƐĞƚĞĐŚŶŽůŽŐŝĞƐƵƉƚŽ ? ? ?ŵŝůůŝŽŶ ?Y>zĚĞƐƉŝƚĞĐŽǀĞƌĂŐĞǁŝƚŚĞǀŝĚĞŶĐĞ
schemes showing limited benefit in clinical practice (17).  
x Health professionals and patients participation in HTpA  
The participation of patients and health professionals is fundamental to HTpA. We believe that 
public consultations on the recommendations are very important and have the power to change 
or improve decisions regarding disinvestment and reinvestment. As indicated in the Guideline, it is 
recommended that public consultation mechanisms are adopted at all stages of the process. This 
includes patient participation in HTpA studies.  
x Medical advocates  
The adoption of clinical practices based on best evidence produced without conflicts of interest 
ensures professionals they are providing their patients with the best possible care within available 
resources. The HTpA process will present the best evidence for the updating of clinical guidelines, 
regardless of the recommendation to disinvest or not.  
"Passive disinvestment" as discussed in the public consultation process, assumes that all medical 
professionals have access to updated scientific evidence from reputable sources and act upon it. 
However, this does not always happen in practice as seen by the continued use of tacrolimus for 
kidney transplantation despite real world evidence supporting greater effectiveness with 
cyclosporine at substantially higher costs (21). . Moreover, physician prescribing can be influenced 
by "success bias" in which prescribers take note of their successful results ignoring cases of non-
success, which may be due to patients not returning, giving the impression that the adopted 
therapeutic approach was optimal when, in fact, it was not.  
x Companies participation in HTpA  
During or soon after incorporation, manufacturers may submit a simplified methodological 
approach for assessing the performance of the technology in routine clinical practice using 
outcome parameters adopted by the submitted cost-effectiveness analysis. It is noteworthy that 
the conduction of HTpA in the country strengthens local and regional company medical and 
pharmacoeconomic divisions. 
x Substitution modality could make the process vicious  
HTpA of technologies incorporated before the adoption of this guideline, and those not prioritized 
during the incorporation process, will occur after indication (demand) and prioritization (Table 1). 
To indicate a technology, or demand a HTpA, the applicant must present at least one study 
showing compliance with at least one of the criteria shown in Table 2. We believe that the 
institutionalization of HTpA will increase the competitiveness of companies.  
x Financing of HTpA studies  
There is room in the national health research agenda for HTpA activities financed by the Ministry 
of Health in Brazil following directives from the Federal Constitution. In addition, new acquisition 
arrangements can be established in which a part of the price paid for the technology is used to 
cover the cost of HTpA activities. We recognize this may be different in other countries. However, 
we believe this is an optimal model ensuring transparency and addressing concerns with conflicts 
of interest.  
x Reallocation of resources  
The Guideline recommends that, whenever possible, it should be stated where and when the 
resources raised by disinvestment will be reinvested, which preferably should be for treatments in 
the same disease area. This should enhance the acceptability of the findings among key 
stakeholder groups.  
3.4 Guideline adjustments and approval of the final version by CONITEC/Brazil and the Ministry 
of Health.  
After presentation of the remarks to the Public Consultation and how these were addressed, the 
final version of the Guideline was accepted in the plenary of the CONITEC and sent for approval of 
the Minister of Health. The approval by the Brazilian Ministry of Health of the Guideline for Heath 
Technology performance Assessment was published on December 2nd 2016, and is now being 
taken forward. We will be assessing its impact in the future to determine whether there should be 
any revisions to the approved Guideline. 
4 CONCLUSION  
The development of the guideline has been an interactive process involving key personnel within 
Brazil and international participants. During its development, we started from the narrow 
objective of evaluating disinvestment to a wider objective of institutionalizing the continuous 
monitoring of funded health technologies in routine clinical care. We believe this has been a 
benefit to all stakeholders concerned. The adoption of the new concept  ? Health Technology 
performance Assessment - makes a distinction between the HTA activities for incorporation, which 
typically only consider controlled studies conducted by the producer for licensing and 
incorporation, and from Health Technology Reassessment, which does not necessarily incorporate 
real-world evidence.  
Institutionalization of HTpA has the potential to continuously improve clinical guidelines to offer 
the best care to patients. In doing so, it may fulfil another important objective: the optimal 
reallocation of health resources  ? reinvestment, for the benefit of the society. It is clear that since 
neglecting care must be firmly avoided, reallocation of resources is automatic. Patients previously 
treated with the disinvested technology will be treated with other more efficient options. In the 
case of therapeutically equivalent generics and biosimilars, the resources released can be used to 
finance the increased demand for healthcare (28).  
Alongside long-term real-world setting evaluations, it is urgent that RCTs conducted for licensing 
and funding assessments be improved. This could be achieved through the choice of more 
pragmatic and meaningful clinical outcome measures (10) and use of a gold-standard treatments 
as control. Both measures may go against the financial interests of companies, but may be 
implemented with stronger regulations by agencies worldwide. Technologies incorporated with 
stronger and credible evidence including outcomes as opposed to surrogate measures, and with a 
justifiable cost, may have the lowest possible chance of ever be indicated or prioritized for HTpA.  
HTpA conducted right from funding decisions may be concurrent with conditional reimbursement 
schemes or managed entry arrangements, both of them conducted when there are concerns 
regarding value for money. Performance assessment adds to these concepts as it is a continuous 
task, reaching longer periods of evaluation and aiming to regularly update clinical guidelines. 
Performance assessment can include comparison with different treatment approaches with the 
rise in electronic health records and other systems to link databases together to assess their 
effectiveness and safety in routine clinical care. 
Two important aspects that can complicate HTpA adoption are the additional costs required and 
the need for more robust administrative and/or clinical data collection and storage. Costs involved 
in HTpA can be seen as an investment to achieve better health care; nevertheless, immediate 
financial resources need to be allocated to improve or create relevant IT systems. In Brazil, the law 
guarantees investment in research related to the public health system, and we believe that part of 
this resource can be allocated to HTpA. Another option valid across countries are arrangements 
with the companies and the creation of research funds. The publication of this Guideline, along 
with the creation of a specific program for HTpA, will allow the institutionalization and continuous 
improvement of the scientific methods to collect real world evidence towards optimization of 
available resources. Disinvestment per se is one of the consequences of HTpA. The 
institutionalization of HTpA will encourage companies to adopt practices to improve quality use of 
their technologies to ensure their effectiveness and cost-effectiveness, favoring patients and the 
health system as a whole.  
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